All News

EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.

AI is welcomed by US adults for streamlining the administrative complexity of getting medical care but not so much for replacing health care professionals themselves.

Your daily dose of the clinical news you may have missed.

New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.

Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Among those treated with lebrikizumab, more than one-third saw clear/almost clear skin at week 16; three-quarters of them maintained results at week 52 with monthly dosing.

Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.

The approval makes dupilumab available to treat uncontrolled CRSwNP in adolescents aged 12 to 17 years, expanding on the current approved range of 18 years and older.

Unawareness was highest among the youngest adults, aged 18 to 44 years, an age range where CV health should be optimized to avoid later morbidity, researchers wrote.

Boehringer Ingelheim announces plans to submit NDA for Investigational Therapy.

Approximately 10.5 million US adults, or 5% of the population, have the atrial fibrillation, according to new prevalence estimates.

The term "flare" is used consistently in discussions of AD, but is everyone talking about the same thing? New research closes in on a patient-centered definition.

Which state retains the most medical residents? Or has the lowest cancer rate? Answers and more insights from a nationwide analysis, here.

The GSK reformulation induced acceptable immune responses for both influenza A and B strains, overcoming a setback earlier in the ability to successfully neutralize the latter.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.